NUVECTIS PHARMA INC's ticker is and the CUSIP is 67080T108. A total of 34 filers reported holding NUVECTIS PHARMA INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3,752,717 | -11.6% | 291,134 | +9.5% | 0.00% | – |
Q2 2023 | $4,247,030 | +60.8% | 265,938 | +32.0% | 0.00% | – |
Q1 2023 | $2,640,786 | +79.8% | 201,433 | +2.9% | 0.00% | – |
Q4 2022 | $1,468,718 | +665.0% | 195,829 | +623.7% | 0.00% | – |
Q3 2022 | $192,000 | -26.4% | 27,061 | +16.4% | 0.00% | – |
Q2 2022 | $261,000 | – | 23,257 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BALDWIN BROTHERS LLC/MA | 116,380 | $1,500,138 | 0.13% |
FORBES J M & CO LLP | 34,000 | $438,260 | 0.06% |
Moran Wealth Management, LLC | 16,697 | $215,224 | 0.01% |
Dorsey Wright & Associates | 1,396 | $17,994 | 0.01% |
Tower Research Capital LLC (TRC) | 7,282 | $93,865 | 0.00% |
MARSHALL WACE, LLP | 36,085 | $465,136 | 0.00% |
Renaissance Technologies | 25,400 | $327 | 0.00% |
UBS Group AG | 3,776 | $48,672 | 0.00% |
RHUMBLINE ADVISERS | 7,273 | $93,742 | 0.00% |
HOLLENCREST CAPITAL MANAGEMENT | 280 | $3,609 | 0.00% |